Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.44 |
| ▸ | PTGES | O14684 | 7/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6471410 | 0.89 | MAPK14 (0.55) | MAPK14PTGESPPARA | |
| SCHEMBL6472056 | 0.81 | MAPK14 (0.47) | MAPK14 | |
| SCHEMBL6473862 | 0.81 | MAPK14 (0.44) | MAPK14 | |
| SCHEMBL6471060 | 0.80 | PTGER1 (0.48) | MAPK14PPARA | |
| SCHEMBL6473088 | 0.80 | MAPK14 (0.48) | MAPK14 | |
| SCHEMBL6533063 | 0.79 | MAPK14 (0.42) | MAPK14PTGES | |
| SCHEMBL6471422 | 0.79 | MAPK14 (0.40) | MAPK14 | |
| SCHEMBL6472895 | 0.77 | MAPK14 (0.37) | MAPK14 | |
| SCHEMBL6471919 | 0.77 | MAPK14 (0.40) | MAPK14PPARA | |
| SCHEMBL6472404 | 0.76 | MAPK14 (0.42) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3691620-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019071147-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2019-04-11 | — | — | WO | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |